API | gandotinib

gandotinib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Gandotinib (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 inhibitor, with additional minor inhibition of STAT3. ^Wikipedia

Chemistry

SMILES: Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
InChIKey: SQSZANZGUXWJEA-UHFFFAOYSA-N
Mol. Mass: 469.95
ALogP: 4.03 Partition coefficient
ChEMBL Molecule:
gandotinib

More Chemistry

Pharmacology

Mechanism of Action:
- Tyrosine-protein kinase JAK2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

gandotinib | ly2784544 | ly-2784544

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Hematologic Neoplasms (Phase 2)

Myeloproliferative Disorders (Phase 1)

Polycythemia Vera (Phase 1)

Primary Myelofibrosis (Phase 1)

Thrombocythemia, Essential (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue